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Background: Interleukin-10 homologues encoded by Herpes viruses such as Epstein-Barr virus (EBV) and human
cytomegalovirus (HCMV) hold interesting structural and biological characteristics compared to human interleukin-10
(hIL-10) that render these proteins promising candidates for therapeutic application in inflammatory bowel disease
(IBD). Intestinal delivery of cytokines using bacterial carriers as chassis represents a novel approach for treatment of
IBD patients. For proof of concept, a Sec-dependent transporter construct was designed for secretory expression of
recombinant viral IL-10 proteins in the periplasm of Escherichia coli laboratory strain BL21 (DE3), which might serve
as part of a prospective lysis based delivery and containment system.
Results: The signal peptide of E. coli outer membrane protein F fused to the mature form of the viral IL-10 proteins
enabled successful transport into the periplasm, a compartment which seems crucial for proper assembly of the dimeric
configuration of the cytokines. Cytokine concentrations in different bacterial compartments were determined by ELISA and
achieved yields of 67.8 ng/ml ± 24.9 ng/ml for HCMV IL-10 and 1.5 μg/ml ± 841.4 ng/ml for EBV IL-10 in the periplasm.
Immunoblot analysis was used to confirm the correct size of the E. coli-derived recombinant cytokines. Phosphorylation of
signal transducer and activator of transcription 3 (STAT3) as part of the signal transduction cascade after IL-10 receptor
interaction, as well as suppression of tumor necrosis factor α (TNF-α) release of lipopolysaccharide-stimulated mouse
macrophages were used as read-out assays for proving in vitro biological activity of the E. coli derived,
recombinant viral IL-10 counterparts.
Conclusions: In this study, proof of principle is provided that E. coli cells are a suitable chassis for secretory
expression of viral IL-10 cytokines encoded by codon-optimized synthetic genes fused to the E. coli ompF signal
sequence. In vitro biological activity evidenced by activation of transcription factor STAT3 and suppression of
TNF-α in mammalian cell lines was shown to be strictly dependent on export of viral IL-10 proteins into the
periplasmic compartment. E. coli might serve as carrier system for in situ delivery of therapeutic molecules in the
gut, thus representing a further step in the development of novel approaches for treatment of IBD.
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Inflammatory bowel disease (IBD), such as Colitis ulcerosa
and Crohn’s disease, present with symptoms like diar-
rhoea, abdominal pain and weight loss which often means
a long ordeal for the patients as well as a great effort for
the health care system. Though wide parts of the under-
lying pathogenesis are still unknown, main components
have been described and open up the opportunity for
novel therapeutic approaches. Profound downregulation
of the auto-inflammatory process has recently been
attempted with antibodies against tumor necrosis factor α
(TNF-α) [1]. A totally new conception is the in situ deliv-
ery of the anti-inflammatory cytokine interleukin-10
(IL-10) via bacterial carrier systems. Steidler et al.
showed decreased inflammation in chemically induced
colitis of mice treated with a Lactococcus lactis strain
secreting murine IL-10 [2].
Since human IL-10 (hIL-10) possesses not only anti-
inflammatory properties like down-regulation of pro-
inflammatory cytokines, inhibition of antigen presentation
on dendritic cells or suppression of major histocompatibil-
ity complex expression, but also displays pro-inflammatory
activity such as stimulation of B-cell maturation and prolif-
eration of natural killer cells [3], IL-10 homologues
encoded by members of the Herpes virus family move
into the focus of interest.
Human cytomegalo- (HCMV) and Epstein-Barr virus
(EBV) perfected their strategies to avoid eradication by
the immune system during co-evolution with the host
[4]. The EBV and HCMV IL-10 counterparts encoded by
the BCRF1 and UL111A gene region, respectively, enable
Herpes viruses among other mechanisms to escape the
host’s immune system and to establish a latent, lifelong
infection. Viral IL-10 homologues share many biological
activities of hIL-10 but, due to selective pressure during
virus evolution, also display unique traits such as in-
creased molecule stability and lack of immunostimulatory
functions [5-7]. These characteristics suggest the viral
counterparts to be even more effective than hIL-10 as
immunosuppressants. Thus, recombinant viral IL-10
(vIL-10) proteins emerge as promising candidates for
therapeutic applications. So far, only EBV IL-10 has
been successfully expressed in both, prokaryotic and
eukaryotic expression systems, which, however, required
further steps to yield a functional protein [8,9].
We aim at using Escherichia coli as chassis for intes-
tinal delivery of recombinant vIL-10 proteins in IBD pa-
tients. In a recent study, we have demonstrated that the
bacterial periplasm is a suitable milieu for expression of
biologically active recombinant IL-10 [10]. An inducible
cell lysis device may then confer both, biological con-
tainment and release of IL-10 into the culture medium
[11]. Thus, as proof of concept, a Sec-dependent vIL-10
transporter was constructed in laboratory E. coli strainBL21 (DE3) which allows secretory expression of codon
optimized viral IL-10 genes in the E. coli periplasm.
Translocation of recombinant viral proteins into E. coli
periplasm was achieved by fusing the signal peptide of
the E. coli outer membrane protein F (OmpF) to the ma-
ture form of the vIL-10 proteins. The biological activity
of the recombinant viral proteins was proved by two inde-
pendent cell-based in vitro assays. To our knowledge, we
describe here for the first time the successful secretory ex-
pression of biologically active viral IL-10 homologues in a
prokaryotic chassis without further purification steps.
Results and discussion
Design and cloning of the artificial vIL-10 transporters
An E. coli codon optimized nucleotide sequence was
generated from the viral IL-10 gene sequences (HCMV
IL-10: 477 bp, GenBank accession number 1LQS_M; EBV-
IL10: 441 bp, GenBank accession number YP_401634). The
original signal sequences of the viral IL-10 genes were re-
placed by the first 66 nucleotides of the ompF gene of E. coli
K12-MG1655 (GenBank accession number NC_000913.2)
coding for the 22 aa long OmpF signal peptide. Using SignalP
3.0 software (www.cbs.dtu.dk/services/SignalP/, Technical
University of Denmark), a high cleavage probability (score
of 0.998) was predicted between aa position 22 and 23
(ANA22 – S23E for HCMV IL-10 and ANA22 – Q23C for
EBV IL-10) delivering the mature form of the vIL-10 pro-
teins with authentic N-terminus.
The E. coli ompF gene was fused in-frame to the 5’ end
of the E. coli codon optimized gene encoding HCMV
IL-10 and EBV IL-10, respectively. The expression of
both synthetic gene constructs was regulated by a T7
promoter. The complete sequence of the artifical vIL-10
transporters including the T7 promoter sequence was syn-
thesized by GeneArt (Regensburg, Germany) and cloned
into a pUC-derived plasmid with ColE1 origin resulting in
the plasmids pGA4 encoding the HCMV IL-10 trans-
porter and pGA6 carrying the EBV IL-10 construct, re-
spectively. The vIL-10 transporter constructs were
subsequently subcloned via an EcoRI restriction site
into pUC19 vector with pMB1 origin. The new expression
vectors, pAZ1c, a derivative of pGA4, and pAZ1e, a de-
rivative of pGA6, were isolated and sequenced. E. coli
BL21 (DE3) cells were transformed with pGA4 and its
corresponding plasmid pAZ1c as well as with pGA6 and
the according plasmid pAZ1e. Plasmid maps of the vec-
tors pAZ1c and pGA6 used in the STAT3 and TNF-α
read-out assays are shown in Figure 1.
Quantification of recombinant vIL-10 expression
The concentration of the viral IL-10 analogues expressed
and secreted in vitro by E. coli strain BL21 (DE3)
containing either plasmid pGA4, pGA6, pAZ1c or pAZ1e


































Figure 1 Plasmid maps of HCMV IL-10 (pAZ1c; A) and EBV (pGA6; B) expression vectors are depicted. The artificial transporter consists of
the E. coli ompF signal sequence fused in frame to E. coli codon optimized mature viral IL-10 genes under control of the T7 promoter. For
subcloning, the constructs are flanked by EcoRI restriction sites. Plasmid pGA6 contains a ColE1, pAZ1c a pUC19-derived pMB1 origin
of replication.
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was obtained by centrifugation while the periplasmic com-
partment was separated from the cytoplasm by using the
osmotic shock procedure as described by Neu and Heppel
[12]. Due to high homology on protein level between
EBV IL-10 and hIL-10 [13], detection of recombinant
EBV IL-10 was possible using a commercial hIL-10
ELISA from R&D Systems (Minneapolis, MN, USA).
For quantification of recombinant HCMV IL-10 in dif-
ferent bacterial cell compartments, an in-house sand-
wich ELISA according to Chang’s description [14] was
established (see Methods).
The mean concentrations of recombinant HCMV IL-10
obtained from an overnight culture of pAZ1c transformed
E. coli BL21 (DE3) were 18.4 ng/ml ± 12.4 ng/ml for the
culture supernatant and 67.8 ng/ml ± 24.9 ng/ml for the
periplasm. Interestingly, in the cytoplasm 18.7 μg/ml ±
12.8 μg/ml of recombinant HCMV IL-10 could be
detected. The mean concentrations of recombinant
HCMV IL-10 found in different cell compartments of
pGA4 transformed E. coli BL21 (DE3) showed three
times lower levels of recombinant protein (data not
shown). Plasmid pGA4 contains a ColE1 origin while
pAZ1c, which is based on expression vector pUC19,
harbors a pMB1 origin, thus resulting in a different
copy number per cell. This may be one reason for the
observed difference in the measured recombinant HCMV
IL-10 concentrations. Since the opposite effect was ob-
served for the EBV IL-10 expression vectors pAZ1e andpGA6, the compatibility of the vIL-10 transporter con-
structs with the different origins of replication present on
the two vector backbones may play a role, too. Due to the
higher yield of recombinant HCMV IL-10 protein from
expression vector pAZ1c, all subsequent experiments
were performed with this plasmid.
The concentration of recombinant EBV IL-10 of pGA6
transformed E. coli BL21 (DE3) were 1.2 ng/ml for culture
supernatant, 1.5 μg/ml ± 841.4 ng/ml for the periplasmic
fraction and 27.8 ng/ml ± 43.4 ng/ml for the cytoplasm.
The concentrations of recombinant EBV IL-10 obtained
from overnight cultures of pAZ1e transformed E. coli
BL21 (DE3) were significantly lower (data not shown), so
all further experiments were carried out with expression
vector pGA6. The vIL-10 concentrations determined for
the different bacterial compartments are summarized in
Table 1.
A number of signal sequences have been employed for
efficient secretory production of heterologous proteins
in E. coli via the Sec-dependent secretion pathway, in-
cluding pectate lyase B (PelB), outer membrane protein
A (OmpA), alkaline phosphatase (PhoA), endoxylanase,
and heat-stable enterotoxin 2 (StII) [15]. The N-terminal
portion of OmpF, a major outer membrane porin of
E. coli, has also been successfully applied for secre-
tion of foreign gene products in E. coli [16]. Most re-
cently, the OmpF leader peptide was successfully used for
secretory expression of biologically active hIL-10 in the
periplasm of E. coli cells [10].
Table 1 Viral IL-10 concentrations in different cell










Supernatant 8.4 ± 12.4 1.2 ± n.d.
Periplasm 67.8 ± 24.9 1500 ± 841.4
Cytoplasm 18700 ± 12800 27.8 ± 43.4
Recombinant vIL-10 concentrations from overnight cultures of E. coli BL 21
(DE3) transformed with either pAZ1c (HCMV IL-10) or pGA6 (EBV IL-10) are
given for different bacterial compartments. Quantification of vIL-10 expression
was accomplished by use of a commercial human IL-10 (for EBV IL-10) and an
in-house sandwich ELISA (for HCMV IL-10), respectively. SD = standard
deviation; n.d. = not done.
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first 22 aa of the OmpF protein to the mature form of
the vIL-10 proteins, an artificial transporter was created
which allowed translocation of both recombinant vIL-10
proteins across the cytoplasmic membrane, thus show-
ing that the modified transporter was in general compat-
ible with the host secretion apparatus. However, the
efficiency of the Sec-dependent preprotein translocation
pathway was different for the two viral IL-10 molecules.
Expression of recombinant EBV IL-10 in E. coli strain
BL21 (DE3) showed much higher protein concentrations
in the periplasm compared to recombinant HCMV IL-
10, for which the concentration in the cytoplasm was
much higher than in other bacterial compartments.
Thus, it seems that the OmpF-EBV IL-10 preprotein is
more compatible with the Sec translocase machinery
than the corresponding HCMV IL-10 molecule. Of note,
the recombinant vIL-10 proteins also appeared in the
culture medium, reaching an amount, which was not
negligible. Given the high EBV IL-10 concentration gra-
dient across the outer cell membrane, the secretion of
the recombinant protein into the culture medium was
not quantitative. Release of recombinant HCMV IL-10
was much higher compared to E. coli-derived EBV IL-10,
thus providing an explanation for the lower concentration
of recombinant HCMV IL-10 protein measured in the
periplasm compared to recombinant EBV IL-10.
Whether secretion of vIL-10 proteins into the culture
medium was selective remained unknown since the
amount of representative periplasmic proteins such as
β-lactamase or alkaline phosphatase was not assessed.
The outer membrane of E. coli contains proteins such
as OmpF, OmpC and others which serve as passive dif-
fusion pores for small hydrophilic molecules [17]. How-
ever, the pores are too small for the vIL-10 molecules to
be released (mol. wt. of the HCMV and EBV IL-10 mono-
mer is 18 and 21 kDa, respectively [18,19]) since the pores’
exclusion limit is a molecular weight of approximately 700
Da [16]. Thus, the mechanism by which recombinant vIL-
10 proteins were translocated across the outer membraneremained unknown. Leakage out of destroyed bacterial
cells would be a reasonable explanation, but would sug-
gest approximately equal amounts of both recombinant
vIL-10 proteins in the culture supernatant.
Immunoblot analysis of E. coli-derived vIL-10 proteins
To further substantiate the results obtained from the
ELISA analysis, Western immunoblot assays were car-
ried out with culture supernatant, peri- and cytoplasmic
fractions of pAZ1c and pGA6 transformed E. coli BL21
(DE3) strains. By using the mature forms of the vIL-10
proteins as commercial standard, the size of the E. coli-
derived recombinant vIL-10 proteins was estimated. Bac-
terial fractions of pUC19 transformed E. coli BL21 (DE3)
served as negative controls. Figure 2 shows a Western
blot of the periplasmic fractions of E. coli BL21 (DE3)
harboring either the expression vector pAZ1c or pGA6.
In the periplasm, vIL-10 products corresponding to the
size of the commercial proteins can be observed, indicat-
ing correct expression of the E. coli codon optimized
vIL-10 genes. The E. coli-derived HCMV and EBV IL-10
proteins migrated at a molecular size of approximately
21 and 18 kDa, respectively, reflecting the size of the
vIL-10 monomers (Figure 2A and 2C). In the reducing
SDS-PAGE immunoblot, the HCMV IL-10 from the
bacterial cytoplasmic fraction migrated at a similar mo-
lecular size compared to the commercial standard and
the recombinant protein from the periplasmic fraction
(Figure 2A), whereas under non-reducing conditions it
ran at a slightly larger size than the commercial standard
and the periplasmic equivalent (Figure 2B). The non-
reducing conditions of the immunoblot might be re-
sponsible for this visible shift due to a change in the
electrophoretic mobility of the full-length HCMV IL-10
protein. HCMV IL-10 protein concentrations in the culture
supernatant were too low to be detectable by the immuno-
blot technique. Western blot analysis of the supernatant
fraction containing E. coli-derived recombinant EBV IL-10
was not carried out.
Whether or not the OmpF signal peptide has been
processed during the translocation across the inner
membrane cannot be judged precisely due to the low
resolution of the immunoblot gel. However, in vitro bio-
logical activity could be proven, thus indicating either a
correct processing of the pre-protein or that the uncleaved
signal peptide does not affect the IL-10 – IL-10 receptor
interaction.
It has been shown that within the IL-10 subfamily of
cytokines only HCMV IL-10 monomers are covalently
linked via a disulfide bond [20]. Thus, immunoblot ana-
lysis under non-reducing conditions is suitable to prove
whether the dimeric state of the E. coli-derived HCMV
IL-10 protein is stabilized by covalent disulfide bond for-
mation. However, no protein dimerization could be
Figure 2 (See legend on next page.)
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Figure 2 Immunoblot analysis of viral IL-10 recombinant proteins. E. coli BL21 (DE3) derived recombinant viral IL-10 proteins were analyzed
by immunoblot in different concentrations and from different cell compartments under both reducing (A = HCMV IL-10; C = EBV IL-10) and non-
reducing conditions (B = HCMV IL-10). Periplasmic and cytoplasmic fractions of pUC19 transformed E. coli BL21 (DE3) cells and commercial viral
IL-10 proteins served as controls. One experiment representative of three is shown. SN = supernatant; PP = periplasmic fraction; CP = cytoplasmic
fraction; Com. = commercial; Rec. = recombinant.
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tions (Figure 2B), indicating that disulfide bond formation
does not occur in E. coli cells during protein translocation
across the inner membrane and thereafter. Of note, it
could be demonstrated that disulfide bridging of both
monomers is not essential for dimerization [21], suggesting
the possibility of a non-covalent assembly of both subunits
as described for hIL-10. Thus, the lack of disulfide bond
formation in the HCMV IL-10 recombinant protein does
not necessarily exclude recovery of its biological activity. A
covalent linkage of both monomers would, however, add to
the stability of the protein, which would be highly desirable
for a prospective in vivo application.
Biological activity of E. coli-derived vIL-10 proteins
Recombinant vIL-10 proteins activate STAT3
The pivotal attribute of viral IL-10 proteins is their
structural similarity to the host’s interleukin counterpart.
As a result, vIL-10 analogues display potent immuno-
suppressive traits, a key factor of the immune escape
mechanism of herpes viruses and the establishment of a
latent infection [4]. Several downstream mechanisms
after binding of vIL-10 to the host’s IL-10 receptor (IL-
10R) as well as consequent immunomodulating effects
have been described, which can be partly traced back to
observable events at the level of cell signal cascade [22].
One well established method to examine in vitro bio-
logical activity of IL-10, no matter of its origin, targets
the recruitment of signal transducer and activator of
transcription 3 (STAT3) as part of the signal transduc-
tion cascade after binding of IL-10 to its receptor [23].
Phosphorylation of STAT3 on aa Tyr705 indicates suc-
cessful IL-10 – IL-10R interaction. We selected an
in vitro cell assay using two different cell lines (murine
macrophages J774.1 and Daudi’s Burkitt lymphoma cells)
for testing the ability of E. coli-derived vIL-10 proteins
to correctly induce the IL-10 signal transduction cas-
cade. Since HCMV IL-10 is known to act only on cells
of human origin due to high species specificity of
HCMV IL-10 [24], we used Daudi’s Burkitt lymphoma
cell line to assess the biological activity of recombinant
HCMV IL-10. For recombinant EBV IL-10, the STAT3
assay was performed on a murine macrophage cell line
since its function is not closely restricted to human spe-
cies [25]. As positive controls, commercial recombin-
ant EBV and HCMV IL-10 from R&D Systems were used.The commercially available viral IL-10 proteins showed
phosphorylation of STAT3 after 1 h of incubation time and
the intensity of immunoblot bands roughly reflected the
IL-10 protein concentration loaded on the gel giving the
assay not only a qualitative but also quantitative character
(Figure 3). Periplasmic fractions of pAZ1c and pGA6
transformed E. coli BL21 (DE3) cells expressing either re-
combinant HCMV or EBV IL-10 were able to activate
STAT3 to a level comparable to stimulation with the com-
mercial vIL-10 proteins. This result indicates the in vitro
biological activity of the E. coli-derived vIL-10 proteins
secreted into the periplasm. It also implies a possible di-
meric state of the secreted vIL-10 proteins which is com-
pulsory for successful IL-10 – IL-10R interaction [26].
However, since an intermolecular disulfide bond forma-
tion could not be demonstrated, a possible non-covalent
assembly of both HCMV IL-10 monomers must be sug-
gested. The biological activity of recombinant vIL-10 pro-
teins released into the culture supernatant could not be
assessed due to low protein concentration.
Interestingly, the cytoplasmic fractions of pAZ1c and
pGA6 transformed E. coli BL21 (DE3) cells showed no
activation of STAT3 (Figure 3), thus being unable to in-
duce the IL-10 signal transduction cascade. This obser-
vation confirms the presumption that most heterologous
proteins expressed in the E. coli cytoplasm do not exist
in a folded and thus functionally active form [27]. Intra-
molecular disulfide bridging is responsible for the high
α-helical content of the vIL-10 protein structures, thus
enabling dimer formation [13,20]. Since the cytoplasmic
compartment lacks chaperones assisting in protein fold-
ing and does not provide a sufficient reducing milieu for
disulfide bond formation, folding and dimerization of re-
combinant vIL-10 proteins is unlikely to occur in the
bacterial cytoplasm [15]. As negative controls, culture
supernatant, periplasmic and cytoplasmic fractions of
pUC19 transformed E. coli BL21 (DE3) cells were used
which did not trigger any phosphorylation of STAT3,
demonstrating no other compound in the bacterial peri-
plasm than the E. coli-derived vIL-10 proteins to be re-
sponsible for stimulation of IL-10R.
The results of the STAT3 in vitro cell assay indicate
the correct folding and dimerization of recombinant
vIL-10 proteins in the bacterial periplasm resulting in
successful interaction with IL-10R and downstream STAT3
recruitment and activation.
Figure 3 Activation of STAT3 by E. coli derived viral IL-10. STAT3 phosphorylation (STAT3-pY705) was analyzed by immunoblot of protein
extracts from human Daudi cells (HCMV IL-10; A) and J774.1 mouse macrophages (EBV IL-10; B) treated with different concentrations of bacteria-
derived viral IL-10. Total STAT3 was used to ensure equal protein loading in all lanes (double bands in Daudi cells represent STAT3 isoforms α and
β). Periplasmic and cytoplasmic fractions of pUC19 transformed E. coli BL21 (DE3) cells and commercial viral IL-10 proteins served as controls. One
experiment representative of two is shown. PP = periplasmic fraction; CP = cytoplasmic fraction; Com. = commercial; Rec. = recombinant.
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biological activity of E. coli-derived EBV IL-10
One of the key characteristics of the IL-10 family is its
anti-inflammatory properties leading to downregulation
of proinflammmatory cytokine and chemokine expres-
sion [22]. Interaction of bacteria with adherent macro-
phages triggers the release of high amounts of the
proinflammatory cytokine TNF-α [28]. Thus, reduced
TNF-α secretion of lipopolysaccharide (LPS) stimu-
lated macrophages can be used as proof of principle to
confirm the functionality of recombinant IL-10 molecules
produced by bacteria. Due to low secretory expression ofrecombinant HCMV IL-10 in E. coli BL21 (DE3), this
read-out system was only tested with E. coli-derived EBV
IL-10. Using the mouse macrophage cell line J774.1, TNF-α
secretion was stimulated by sterile-filtered periplasm of
pUC19 transformed E. coli BL21 (DE3) cells. Previous ex-
periments with highly purified commercial LPS showed
that absolute levels of TNF-α in the supernatant were too
low to properly assess a significant reduction after IL-10
addition. However, the LPS content of the periplasmic
fraction of pUC19 transformed E. coli BL21 (DE3) cells
grown overnight to similar OD600 values proved to be
stable enough for the induction of consistent TNF-α levels
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J774.1 cells (data not shown). Both, the periplasmic frac-
tion of pGA6 transformed E. coli BL21 (DE3) cells
containing the secreted from of recombinant EBV IL-10
as well as the commercial analogue (R&D Systems) were
able to significantly suppress TNF-α secretion of LPS-
stimulated J774.1 mouse macrophages after 4 h of incuba-
tion (Figure 4). Compared to the TNF-α concentrations in
the culture medium of the induction controls, periplasmic
fractions of pGA6 transformed E. coli BL21 (DE3) cells
were able to reduce the TNF-α level by 49 ± 20%. These
values were within the same range of the commercial EBV
IL-10 standard, which suppressed TNF-α levels by 57 ±
23%. Pre-incubation of either the periplasmic fraction of
pGA6 transformed E. coli BL21 (DE3) cells or the com-
mercial EBV IL-10 with an EBV IL-10 specific neutralizing
antibody (R&D Systems) abrogated the suppression of
TNF-α secretion, thus indicating an exclusive dependence
of reduction of TNF-α release on the secreted interleukin.
The results of the TNF-α cell assay further substantiate




























Figure 4 Inhibition of LPS-induced TNF-α release by E. coli
derived recombinant EBV IL-10. J774.1 mouse macrophages were
incubated with E. coli BL21 (DE3) pGA6 periplasmic fraction alone
(bacterial recombinant EBV IL-10 at ~ 400 ng/ml) or in the presence
of neutralizing monoclonal anti-EBV IL-10 antibody. Periplasmic
fractions of E. coli BL21 (DE3) pUC19 were used as TNF-α induction
control. Commercial EBV IL-10 (at ~ 400 ng/ml) served as positive
control. TNF-α induction levels were set at 100%, and changes of
TNF-α release are the means ± SD of four independent experiments.
Statistical significance was determined using the Student t-test. Asterisks
indicate statistically significant differences (* p ≤ 0.05; ** p ≤ 0.01)
between pGA6 PP, pUC19 PP, and pGA6 after anti-EBV IL-10 treatment.
PP = periplasmic fraction; Com. = commercial; Rec. = recombinant;
mAb = monoclonal antibody.into the periplasmic space of E. coli BL21 (DE3) cells
shows in vitro biological activity.
Conclusions
The results presented in this study demonstrate that
E. coli cells are a suitable chassis for secretory expres-
sion of in vitro biologically active vIL-10 analogues.
Due to the potent anti-inflammatory traits of these
molecules, E. coli cells genetically modified for secretory
expression of cytokines may be used as carriers for in situ
intestinal cytokine delivery. The study clearly demon-
strates that recovery of recombinant vIL-10 proteins with
biological activity is only possible when the proteins were
trapped in the bacterial periplasm. This phenomenon was
also observed for the expression of hIL-10 in a previous
study [10]. Furthermore, our results demonstrate that the
Sec-dependent E. coli OmpF leader peptide is a suitable
export signal for other members of the IL-10 subfamily al-
though the viral IL-10 proteins only share 27 – 83% amino
acid sequence identity with hIL-10 [13,19]. Other attempts
using bacterial transporters, which enable a direct secre-
tion of recombinant IL-10 into the culture medium such
as the E. coli hemolysin system, did not result in successful
secretion of a biologically active molecule [29]. Conse-
quently, the best strategy in the development of a carrier
for the in situ intestinal IL-10 delivery seems to be the
periplasmic production of the protein and its subsequent
release from the carrier via a cell lysis system. For future
in vivo applications, a controlled release of the recombin-
ant vIL-10 proteins as well as the biological containment
of the genetically modified bacteria is mandatory. For ex-
ample, Kong et al. have developed an arabinose-dependent
lysis system for the in vivo delivery of vaccine antigens [11]
which combines both release of bacteria expressed proteins
and containment of genetically engineered bacterial car-
riers. The realization of such a construct for IL-10 would
then blaze the trail for testing IL-10 expression in a murine
IBD model. In this way, IBD might be prospectively treated
in a selective and strict topical manner, thus avoiding sys-
temic side effects as known from other immunosuppres-
sive drugs.
Methods
Restriction enzymes, proof-reading Phusion DNA poly-
merase and T4 DNA ligase were purchased from New
England Biolabs (Beverly, MA, USA) and were used
according to the manufacturer’s instructions. GoTaq DNA
polymerase was from Promega (Madison, WI, USA). DNA
sequencing kits (ABI PRISM BigDye Terminator v3.1 Cycle
Sequencing Kit) were obtained from Applied Biosystems
(Darmstadt, Germany). Oligonucleotide primers were syn-
thesized by biomers.net (Ulm, Germany). Kits for plasmid
mini-prep and PCR purification as well as DyeEx 2.0 Spin
Kits for clean-up of sequencing reaction were all purchased
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were from Omni Life Science (Bremen, Germany).
Prestained molecular mass marker BenchMark® for
SDS-PAGE electrophoresis and nitrocellulose mem-
branes for protein blotting were obtained from Life
Technologies (Darmstadt, Germany). Reducing sample
buffer containing 100 mM dithiotreitol as well as a de-
tection kit for enhanced chemiluminescence (ECL
SuperSignal West Pico Substrate) was procured by
Thermo Fisher Scientific (Dreieich, Germany). Vivaspin 20
concentrators (10000 MWCO PES) for enrichment of re-
combinant vIL-10 proteins in different cell fractions were
purchased from Sartorius (Göttingen, Germany). Culture
medium components were supplied from BD (Franklin
Lakes, NJ, USA). J774.1 cells were cultivated in complete
Iscove’s medium procured from Biochrom (Berlin, Germany)
supplemented with 10% (v/v) FCS while DAUDI cells were
grown in RPMI 1640 liquid medium with stable glutamine
containing 20% (v/v) FCS. All cell lines were maintained at
37°C in 5% CO2/95% air. Other chemicals obtained from
commercial sources were all of analytical grade and were
used without further purification.
Bacterial strains, plasmids and growth conditions
Cloning experiments were performed in Escherichia coli
MDS 42 [30] obtained from Scarab Genomics (Madison,
WI, USA) while protein expression analysis was carried
out in Escherichia coli BL21 (DE3) [F- ompT hsdSB (rb
- mB
-)
gal dcm (λDE3)] obtained from New England Biolabs.
Plasmids used in this study were pUC19 (New England
Biolabs,), pGA4 and pGA6 (GeneArt). Cells were generally
grown aerobically either in liquid (shaking) or on solid
Luria-Bertani (LB) medium (1% bactotryptone, 0.5% yeast
extract, and 0.5% sodium chloride) [31] at 37°C. Media
were supplemented when appropriate with ampicillin
(100 μg/ml; Sigma Aldrich, St. Louis, MO, USA).
DNA sequencing
Nucleotide sequencing of the modified transporter con-
struct inserted in pAZ1c and pAZ1e expression plasmids
was performed following the application of automated
DNA sequencing method based on the dideoxy chain
termination method [32], using M13 primers for both
plasmids.
Transformation of E. coli strains
E. coli strains were made competent and transformed
using standard techniques [33]. Briefly, either a 20-ng
aliquot of the ligation mixture or the corresponding se-
quenced plasmid was added to 40 μl of electrocompetent
E. coli cells, and the mixed solution was transferred into
an ice-cold 0.2-cm disposable cuvette (Bio-Rad Laborator-
ies, Hercules, CA, USA). Electroporation was conducted
using a Gene Pulser Xcell electroporation system (Bio-RadLaboratories) at 2.5 kV, 25 μF, and 400 Ω and was imme-
diately followed by the addition of 1 ml of SOC medium
(SOB medium containing 20 mM glucose, 10 mM
MgSO4, and 10 mM MgCl2). The culture was then in-
cubated for 1 h at 37°C. 10 μl and 100 μl aliquots as
well as the rest volume were spread onto LB agar
containing 100 μg/ml ampicillin and incubated overnight
at 37°C to select for the antibiotic-resistant recombinants.
Successful transformants were confirmed by mini-prep
growth with plasmid extraction followed by restriction di-
gestion and gel electrophoresis.
Construction of the EBV and HCMV IL-10 expression
vectors
Molecular methods were performed as described by
Sambrook et al. [34]. To construct plasmids pGA4 and
pGA6, 700 and 664 bp DNA fragments including the T7
promoter and the first 66 nucleotides of the E. coli ompF
gene (NC_000913.2) encoding the signal peptide se-
quence fused in frame to E. coli codon optimized genes
of the mature form of either HCMV IL-10 (1LQS_M) or
EBV IL-10 (YP_401634) were de novo synthesized and
cloned into SacI/KpnI digested pUC-derived vector
pMA by GeneArt. The pGA4 and pGA6 plasmids were
EcoRI digested and the resulting DNA fragments includ-
ing the vIL-10 transporter construct and the T7 pro-
moter region were subsequently ligated into EcoRI
digested pUC19 resulting in the expression plasmids
pAZ1c and pAZ1e.
Viral IL-10 sample preparation
E. coli BL21 (DE3) cells transformed with the HCMV
and EBV IL-10 expression plasmids pGA4, pGA6, pAZ1c
and pAZ1e were grown overnight at 37°C in 50 ml of LB
broth containing 100 μg/ml of ampicillin. From overnight
cultures, the culture supernatant was removed and sterile fil-
tered (0,2 μm, Filtropur S; Sarstedt, Nümbrecht, Germany).
The periplasmic fraction was prepared according to the
method of Neu et al. [12]. Briefly, the cell pellet was
resuspended in ice-cold protoplast buffer containing 30 mM
Tris–HCl, 40% sucrose (w/v), and 2 mM EDTA at 1/10 of
the culture volume. After 15 min of incubation on ice, the
cells were centrifuged at 5000 rpm for 60 min at 4°C.
The supernatant fluid was discarded, and the pellet
was resuspended in a volume of cold water equal to
that of the original volume of the suspension. After 15
min of incubation on ice and centrifugation, the super-
natant fluid equivalent to the periplasmic fraction was
collected. The remaining pellet resembling the cells’
cytoplasm was washed twice, resuspended in cold
water and subsequently centrifuged. To solubilize the
cytoplasmic fraction, the washed pellet was resuspended
in cold water again, treated constantly for two minutes by
sonification using Sonopuls HD 70 (Bandelin electronic,
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cedure was repeated until the visible pellet was gauzy.
Viral IL-10 sandwich ELISA
Recombinant HCMV IL-10 levels were quantified by
using an in-house ELISA according to Chang’s descrip-
tion [14]. Briefly, 96 well microplates (#2592; Corning
Life Sciences, Corning, USA) were coated with anti-
HCMV IL-10 polyclonal antibodies (R&D Systems) at a
concentration of 1 μg/ml overnight at 4°C. After washing
three times with PBS containing 0.05% Tween 20
(AppliChem, Darmstadt, Germany), plates were blocked
with 3% (w/v) bovine serum albumin in PBS at 37°C for
1 h followed by three washing steps. Bacterial samples as well
as commercial recombinant HCMV IL-10 (R&D Systems)
used as standard at a concentration range from 5 ng/ml to
312.5 pg/ml were incubated for 1 h at 37°C. After washing
four times, wells were incubated with 1 μg/ml anti-HCMV
IL-10 biotinylated antibodies (R&D Systems) for 1 h at
room temperature. After four washing steps, Streptavidin
horseradish peroxidase (HRP) conjugate (R&D Systems) at
a dilution of 1:2000 was incubated at room temperature
for 30 minutes followed by six washing steps. Finally,
tetramethylbenzidine (TMB) substrate (Life Technologies)
was added at room temperature, and the colorimetric
reaction was stopped after 30 min with 1 N hydrochloric
acid. Intra-assay and inter-assay variance were calculated
4.4% and 5.5%, respectively.
The concentration of recombinant EBV IL-10 was
measured using the Quantikine® kit for human IL-10
from R&D Systems. The assay was carried out according
to the manufacturer’s instructions.
All samples were measured in duplicate at 450 nm
with wavelangth correction of 540 nm. Cytokine levels
were determined by linear regression analysis using a
standard curve generated with the supplied calibration
material in case of EBV IL-10 or the commercial recom-
binant HCMV IL-10 protein standard (R&D Systems),
respectively. As negative controls served supernatant and
periplasmic fraction from pUC19 transformed E. coli BL21
(DE3). The vIL-10 concentrations are the result of three
independent experiments and presented as mean ± SD.
SDS PAGE vIL-10 immunoblot analysis
Enrichment of recombinant vIL-10 from periplasmic
fractions of pAZ1c and pGA6 transformed E. coli BL21
(DE3) cells was performed with Vivaspin 20 concentra-
tors (exclusion limit 10000 MWCO) obtained from
Satorius Stedim Biotech (Göttingen, Germany). Periplas-
mic fractions were separated by SDS-PAGE on a 10%
(w/v) NuPAGE Novex Bis-Tris gel (Life Technologies)
prior to blotting onto nitrocellulose which was blocked
for 1 h with blotting solution consisting of 25 mM Tris,
0.15 M NaCl and 0.1% Tween 20 at pH 7.4 supplementedwith 3% (w/v) BSA. Membranes were incubated overnight
at 4°C with either a goat anti-HCMV IL-10 biotinylated
antibody (R&D Systems; 100 ng/ml diluted at 1:500) to
detect HCMV IL-10 or a mouse anti-EBV IL-10 antibody
(R&D, Minneapolis, USA; 2 μg/ml diluted at 1:250) to de-
tect EBV IL-10. After washing, a second 1 h incubation
step followed at room temperature with either a HRP-
conjugated goat anti-mouse immunoglobulin G (IgG)
(R&D, Minneapolis, USA) diluted at 1:1000 for detection
of EBV IL-10 or with streptavidin HRP conjugate (R&D,
Minneapolis, USA) at a dilution of 1:2000 for detection of
HCMV IL-10.
Chemoluminescence was detected by incubation
with TMB-H2O2 as substrate (Super Signal West Pico
Chemoluminescent Substrate Kit, Thermo Scientific)
according to the manufacturer’s manual and subse-
quent analysis with a LAS 3000 (FUJIFILM Europe,
Düsseldorf, Germany) bioimager. Commercial vIL-10s
(R&D Systems) were used as standard. SDS-PAGE im-
munoblot data were the result of at least two inde-
pendent experiments.
In vitro assays for characterization of vIL-10 biological
activity
Biological activity of recombinant EBV IL-10 was tested
on murine macrophage cell line J774.1, whereas for re-
combinant HCMV IL-10 the human Burkitt lymphoma
DAUDI cell line were used.
a) STAT3 cell assay
Cells were incubated for 30 min at 5 × 106 per well
with recombinant vIL-10 from the periplasmic fraction
of either pAZ1c or pGA6 transformed E. coli BL21
(DE3) cells, then harvested and treated with cell
lysis buffer (RIPA buffer; Sigma Aldrich) containing
inhibitors of proteases (Complete Mini; Roche Applied
Science, Mannheim, Germany) and phosphatases
(Phosphostop; Roche Applied Science, Mannheim,
Germany) for 1 h on ice. Cell lysates were clarified
by centrifugation, and the supernatants were then
analyzed by SDS-PAGE on a 10% (w/v) NuPAGE
Novex Bis-Tris gel (Life Technologies) and subsequent
Western blotting with polyclonal antibodies directed
against either phospho-STAT3 (Y705) (Cell Signaling
Technology, Danvers, MA, USA) or total STAT3
(C-20; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), both diluted at 1:1000 in TBS buffer
supplemented with 0.1% (v/v) Tween 20 and 5%
(w/v) BSA. HRP-conjugated goat anti-rabbit IgG
(Jackson ImmunoResearch, West Grove, PA, USA)
diluted at 1:15000 in TBS-T buffer containing 3%
BSA was utilized for detection. Mild stripping was
performed using a buffer containing 1.5% glycin
(w/v), 0.1% sodium dodecylsulfate and 1% (v/v)
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plasmic fraction of pUC19 transformed E. coli BL21
(DE3) and commercial vIL-10 (R&D Systems) were
used as controls. STAT3 immunoblot data were the
result of at least two independent experiments.
b) TNF-α cell assay for E. coli-derived EBV IL-10
Prior to the experiment, J774.1 cells were seeded at a
density of 5 × 104/ml in tissue culture plates and were
then incubated for 2 h at 37°C. Recombinant EBV
IL-10 from the periplasmic fraction of pGA6
transformed E. coli BL21 (DE3) cells was either
preincubated alone or in the presence of 3 μg/ml
neutralizing anti-EBV IL-10 monoclonal antibody
(R&D Systems) for 20 min at 37°C, filled up to equal
volumes with LPS containing periplasmic fraction of
pUC19 transformed E. coli BL21 (DE3) cells, and then
added to J774.1 cells at a concentration of ~ 400 ng/ml.
After 4 h of incubation at 37°C, the amount of
TNF-α released in the medium was measured in
duplicate by ELISA (R&D Systems) according to the
manufacturer’s instructions. Periplasmic fraction of
pUC19 transformed E. coli BL21 (DE3) was used as
TNF-α induction control. Commercial EBV IL-10
(R&D Systems) served as positive control. Presented
values were the result of four independent experiments.
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